Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To report the efficacy of subconjunctival triamcinolone (Kenalog A-40, Alcon) and bevacizumab (Avastin, Genentech) injections in fraternal twins with blepharokeratoconjunctivitis (BKC) causing progressive, bilateral corneal neovascularization and scarring.
Methods: In this retrospective observational case series, two three-year-old male twins with BKC had presented with bilateral red eyes, photophobia, and frequent blinking. Examination of each child showed bilateral deep stromal and superficial corneal neovascularization, corneal infiltrates, multiple follicles on the palpebral conjunctiva bilaterally with blepharitis, and thick turbid sebum expressed from the Meibomian glands. Their disease progressed despite conventional treatment. Both twins were managed with subconjunctival triamcinolone injection and subconjunctival bevacizumab injection of each eye.
Results: The treatment resulted in improvement of symptoms, and examination over an 8-10-month period postinjections showed fading stromal corneal infiltrates, partially regressed corneal neovascularization, and reduced conjunctival injection without complications.
Conclusion: This case series highlights the potential vision threatening complications of BKC. In addition to conventional management options, this report is the first published use of subconjunctival triamcinolone and bevacizumab injections for BKC in children in an attempt to minimize and improve corneal neovascularization and scarring and subsequently to retain useful vision.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008772 | PMC |
| http://dx.doi.org/10.1155/2018/2602487 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Subconjunctival Triamcinolone with Topical Prednisolone for Routine Anti-Inflammatory Prophylaxis in Manual Small Incision Cataract Surgery: A Single-Center, Randomized Controlled Trial Pilot Protocol.
Clin Ophthalmol
July 2025
Seva Foundation, Berkeley, CA, USA.
Background: Cataract surgery is the most commonly performed operation worldwide. Prophylaxis against postoperative endophthalmitis and inflammation currently includes perioperative, patient-administered instillation of topical antibiotic and anti-inflammatory drops in the US, Europe and Latin America. As patients can face challenges with adherence to topical drops for self-instillation, injected drugs may offer a solution.
View Article and Find Full Text PDFSubconjunctival Steroids for Conjunctival Benign Reactive Lymphoid Hyperplasia.
Ocul Oncol Pathol
June 2025
Queensland Ocular Oncology Service, Spring Hill, QLD, Australia.
Introduction: Conjunctival benign reactive lymphoid hyperplasia (CBRLH) is a rare, polyclonal lymphoproliferative disorder on the benign end of the spectrum of lymphocytic infiltrative disorders. There is currently no established standard of care, and various treatment options have been explored. This 2-patient case series highlights the successful use of subconjunctival triamcinolone acetate as an effective therapeutic approach, contributing to the growing body of literature on CBRLH management.
View Article and Find Full Text PDFComparison of Postoperative Intraocular Inflammation in Dogs Receiving Transzonular Intravitreal Triamcinolone-Moxifloxacin Versus Subconjunctival Triamcinolone After Phacoemulsification.
Vet Ophthalmol
April 2025
Animal Eye Care, Newport News, Virginia, USA.
Objective: To evaluate the postoperative effect of transzonular intravitreal triamcinolone-moxifloxacin compared to subconjunctival triamcinolone administered during phacoemulsification in dogs.
Animals Studied: Forty-eight dogs (96 eyes) undergoing bilateral phacoemulsification and intraocular lens implantation.
Procedures: All dogs undergoing phacoemulsification and intraocular lens implantation received transzonular intravitreal triamcinolone-moxifloxacin (TITM) in one eye and subconjunctival triamcinolone (SCT) in the contralateral eye.
Triamcinolone acetonide and botulinum toxin A for upper eyelid retraction in thyroid-associated ophthalmopathy.
Sci Rep
February 2025
Department of Ophthalmology, The First Hospital of Putian City, 351100, Putian, China.
To evaluate the therapeutic effect of combining subconjunctival botulinum toxin A (BTX-A) with periorbital triamcinolone acetonide (TA) injections in treating upper eyelid retraction (UER) due to thyroid-associated ophthalmopathy (TAO). Fifty eyes with TAO-related UER were randomized into two groups. Group 1 received TA alone, while group 2 received BTX-A plus TA.
View Article and Find Full Text PDFMorphological and Histological Changes Following Triamcinolone Injection Alone or Mixed Injection of Triamcinolone and Botulinum Toxin in Upper Eyelid.
J Craniofac Surg
June 2025
Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.
Objective: The purpose of this experiment was to evaluate the functional and histologic changes in the upper eyelid muscles after injection of triamcinolone acetonide (TA) alone or TA combined with botulinum toxin A (Botox or BTXA) in the cynomolgus monkey model.
Methods: Twenty eyes of 10 cynomolgus monkeys were divided into 4 groups: 3 experimental groups (1, 2, and 3) and the control group (group 4) based on the injection type. In group 1, 0.